Key Highlights

  • The exclusive contract sales and Marketing arrangement with DKSH Singapore for orthopaedic products ends on 31 December 2026.
  • Osteopore International will take over sales and marketing in Singapore from 1 January 2027, after a transition period.
  • The arrangement was originally signed in November 2024 as a five-year exclusive agreement.
  • The company has established 3D printing services and plans injectable regenerative bone fillers for the same customer group.

Osteopore Limited (ASX:OSX) announced on 2 November 2026 that its subsidiary, Osteopore International Pte Ltd, and DKSH Singapore Pte Ltd have agreed to end their exclusive contract sales and marketing arrangement for the company's orthopaedic products in Singapore, effective 31 December 2026. The company is a regenerative medicine Business that manufactures 3D-printed biomimetic and bioresorbable implants, and the announcement sets out the reasons for bringing the business in-house ahead of the scheduled expiry.

Terms of the Transition

The agreement with DKSH is being concluded ahead of its scheduled expiry. Following an agreed transition period, Osteopore International will assume responsibility for sales and marketing of the orthopaedic business in Singapore from 1 January 2027. The company said the change is intended to strengthen its focus on the orthopaedic business in its home market and to streamline and improve customer interaction.

The original five-year exclusive contract sales and marketing agreement with DKSH was announced on 6 November 2024 and covers the company's off-the-shelf products for bone loss treatment in the upper and lower extremities. The company said the products have gained adoption in several Singapore hospitals and clinics with DKSH's support, and it thanked the DKSH team for its work over the past two years.

The announcement describes the transition as a planned change, with the DKSH arrangement ending ahead of its scheduled expiry. The company has not disclosed the value of sales made through DKSH, which means that the scale of the change for the business cannot be measured from the announcement alone.

Product and Service Developments

The announcement links the change to Osteopore's establishment of 3D printing services, which it first announced on 10 February 2026. It also refers to the planned introduction of injectable regenerative bone fillers that target the same group of customers. The company said these developments make direct management of the Singapore orthopaedic business more important.

The company's description of adoption in Singapore hospitals and clinics is qualitative, and the announcement does not provide numbers on product uptake. The company said the change is intended to make customer interaction more direct, which is consistent with the greater control of sales that direct selling typically provides.

Scope of the Announcement

The announcement is brief and focused on the distribution arrangement. It does not give financial figures for the orthopaedic business, the cost of the transition or the Revenue contribution of the Singapore operations.

The announcement also reflects the company's view that the Singapore business is its home market for the orthopaedic range. Osteopore International is a Subsidiary of the group, and the announcement describes the change as bringing the sales function within the company's existing structure from 1 January 2027.

Sector Context and Risks to Watch

Medical device and regenerative medicine companies often use distributors in overseas markets during early commercialisation, and some move to direct sales once they have built local clinical relationships and expanded their product range. The announcement reflects this pattern in its reference to 3D printing services and injectable regenerative bone fillers.

The risks named or implied in the announcement are the transition period between distributor and direct sales, the timing of product launches and the need to maintain customer relationships during the handover. Future announcements may show whether direct selling begins on 1 January 2027 as planned and whether the new products are introduced into the same customer group.

Final Word

The announcement moves the Singapore orthopaedic business from a distributor-led model to direct selling from January 2027. The company did not provide financial effects in the announcement, so the outcome will depend on the transition period and on the launch timing of the new products it has referred to.